Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Chlodantane and Semax — mechanism, dosing, side effects, legal status, and pricing.
Chlodantane (ADK-910) is a non-peptide aryl-substituted 2-aminoadamantane amide, structurally related to bromantane and classified in Soviet pharmacological literature as an actoprotector/adaptogen. It has never been approved for human use in any jurisdiction and remains entirely unevaluated in clinical trials. All available data derive from animal and cell-culture experiments conducted in the former Soviet Union.
Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from ACTH(4-10) with a Pro-Gly-Pro C-terminal extension for metabolic stability. It was developed at the Institute of Molecular Genetics (Russian Academy of Sciences) and registered as a drug in Russia in 1994. It is not FDA-approved.
Chlodantane
Semax
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Chlodantane
No pricing data yet.
Check Chlodantane prices →Semax
COA corpus from Disclosed Labs — independently tested batches only.
Chlodantane
1
COAs
99.9%
Avg purity
1
Labs
Semax
82
COAs
99.5%
Avg purity
16
Labs
No human data exist; a 2012 review explicitly states that all pharmacological data derive from animal or cell-culture experiments, with no clinical research conducted. In unspecified animal models, chlodantane enhanced resistance to physical and toxic-chemical stressors, produced immunostimulating effects in stress-induced immunodeficiency, and protected against hypoxia, high and low ambient temperature, and toxic chemical challenge. Effects were reported to appear after a single administration, and immunostimulant activity was described as more pronounced than that of bromantane.
Semax's evidence base is primarily Russian-language clinical literature. Gusev, Skvortsova and colleagues reported improved neurological recovery in acute hemispheric ischemic stroke when Semax was added to conventional therapy (Zh Nevrol Psikhiatr, 1997; PMID 11517472), and subsequent Russian studies extended use to cerebrovascular insufficiency (PMID 15792140). Preclinical work by Dolotov, Myasoedov and colleagues demonstrated that intranasal Semax rapidly elevates BDNF protein and TrkB activation in rat hippocampus and basal forebrain (Brain Res 2006, PMID 16996037; J Neurochem 2006, PMID 16635254). Genome-wide transcriptional analysis by Medvedeva et al. in rat focal ischemia showed Semax modulates a broad panel of immune-response and vascular-system genes (BMC Genomics 2014, PMID 24661604). Western evidence is limited; Semax has not been evaluated by the FDA and has no pivotal trials in the US or EU.
Chlodantane (Performance) and Semax (Cognitive) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Half-life
Side Effects
Contraindications
Lab Testing
Disclosed Labs